CliffBio
small molecule

CABAZITAXEL

CABAZITAXEL

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameCABAZITAXEL
Active ingredientCABAZITAXEL
Strength60MG/1.5ML (40MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2023
Marketing statusDISCN

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.